



# Balfour Capital Group Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company headquartered in New York City. Founded in 1849, it focuses on the discovery, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas, including oncology, immunology, cardiology, endocrinology, and neurology. Notably, Pfizer developed the COVID-19 vaccine Comirnaty in partnership with BioNTech, marking a significant contribution during the pandemic.

## 1. Top 5 Competitors

Pfizer's main competitors in the pharmaceutical industry are:

1. Johnson & Johnson
2. Roche Holding AG
3. Eli Lilly and Co.
4. AbbVie Inc.
5. Merck & Co.

These companies are major players in the global pharmaceutical market, offering a range of products that compete with Pfizer's offerings.

## 2. Largest Institutional Shareholders

As of March 31, 2025, the largest institutional shareholders of Pfizer are:

- Vanguard Group Inc. – 523.17 million shares (9.20%)
- BlackRock Inc. – 474.17 million shares (8.34%)
- State Street Corp. – 296.97 million shares (5.23%)

These institutions hold significant stakes in Pfizer, reflecting confidence in the company's long-term prospects.

## 3. Management Team

Pfizer's executive leadership team includes:

- Dr. Albert Bourla – Chairman and Chief Executive Officer
- David M. Denton – Chief Financial Officer and Executive Vice President
- Douglas M. Lankler – Chief Compliance and Risk Officer
- Sally Susman – Chief Corporate Affairs Officer and Executive Vice President

This team is responsible for steering Pfizer's strategic direction and operational execution.



# Balfour Capital Group Pfizer Inc.

## 4. Revenue

For the full year 2024, Pfizer reported total revenues of \$63.6 billion, reflecting a 7% year-over-year operational growth. Excluding contributions from COVID-19 products, revenues grew 12% operationally.

## 5. Institutions with Buy Recommendations:

As of May 2025, several institutions have issued buy recommendations for Pfizer's stock. For instance, Zacks Investment Research reports that out of 24 analyst recommendations, 9 are "Strong Buy," representing 37.5% of all recommendations.

## 6. Analyst Sentiment Summary

Analyst sentiment for Pfizer is currently mixed. According to Stock Analysis, the average analyst rating is "Hold," indicating expectations for the stock to perform in line with the overall market. The average target price is \$28.26, suggesting potential upside from current levels.

## 7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, insider activity at Pfizer has been predominantly selling. Notably, in the past 90 days, there has been one insider trading transaction: Jennifer B. Damico, Senior Vice President & Controller, sold 2,500 shares on March 4, 2025. This transaction reflects a net value of approximately \$64,825.